Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University Hospital Freiburg Hoffmann-La Roche |
---|---|
Information provided by: | University Hospital Freiburg |
ClinicalTrials.gov Identifier: | NCT00411515 |
The purpose of this prospectively randomized multicentre study was to prove the efficacy and safety of mycophenolate mofetil (MMF) to preventing graft rejection and improvement of clear graft survival following high-risk keratoplasty. The patients of the MMF group receive MMF orally 2x1 g daily for 6 months. Endpoints were immune reaction free and clear graft survival and the occurence of side-effects.
Condition | Intervention | Phase |
---|---|---|
Corneal Transplantation |
Drug: Mycophenolate Mofetil 2x 1g |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Germany | |
University Eye hospital | |
Freiburg, Germany, 79106 |
Study Chair: | Thomas Reinhard, Prof. MD | University eye hospital Freiburg |
Study ID Numbers: | FR-2000-05-2006-06 |
Study First Received: | December 12, 2006 |
Last Updated: | December 14, 2006 |
ClinicalTrials.gov Identifier: | NCT00411515 History of Changes |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Anti-Bacterial Agents Immunologic Factors Mycophenolic Acid Mycophenolate mofetil Immunosuppressive Agents |
Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Therapeutic Uses Physiological Effects of Drugs Mycophenolic Acid |
Mycophenolate mofetil Enzyme Inhibitors Antibiotics, Antineoplastic Immunosuppressive Agents Pharmacologic Actions |